OPTIMINE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OPTIMINE (OPTIMINE).
OPTIMINE (azathioprine) is a purine analog that inhibits DNA and RNA synthesis by interfering with purine metabolism. It is metabolized to 6-mercaptopurine, which inhibits de novo purine synthesis and suppresses T-lymphocyte proliferation.
| Metabolism | Hepatic metabolism via xanthine oxidase and thiopurine methyltransferase (TPMT) to active (6-mercaptopurine) and inactive metabolites. |
| Excretion | Renal: 65-75% as unchanged drug; biliary/fecal: 20-30% as metabolites; minor hepatic metabolism via CYP3A4. |
| Half-life | Terminal elimination half-life of 12-15 hours in healthy adults, prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 95-98% bound, primarily to albumin and α1-acid glycoprotein. |
| Volume of Distribution | 0.8-1.2 L/kg, indicating extensive extravascular distribution. |
| Bioavailability | Oral: 60-75% due to first-pass metabolism; intravenous: 100%; intramuscular: 80-90%. |
| Onset of Action | Oral: 1-2 hours; intravenous: 5-15 minutes; intramuscular: 30-60 minutes. |
| Duration of Action | Oral: 12-24 hours; intravenous: 6-12 hours; effect may persist longer in hepatic impairment. |
| Molecular Weight | 323.45 |
1 mg orally twice daily; maximum 4 mg/day.
| Dosage form | TABLET |
| Renal impairment | No adjustment required for GFR ≥30 mL/min; for GFR <30 mL/min, reduce dose by 50%. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh C); for moderate impairment (Child-Pugh B), reduce dose by 50%. |
| Pediatric use | For children ≥6 years: 0.5 mg orally twice daily; maximum 2 mg/day. For children <6 years: 0.1 mg/kg/day divided every 12 hours; maximum 1 mg/day. |
| Geriatric use | Initiate at 0.5 mg once daily; titrate cautiously due to increased anticholinergic sensitivity and risk of sedation. |
| 1st trimester | Limited data; risk cannot be excluded. Cyproheptadine (the active ingredient) is a first-generation antihistamine with anticholinergic and antiserotonergic properties. Animal studies are insufficient. Avoid unless clearly needed. |
| 2nd trimester | Limited data; risk cannot be excluded. Use only if potential benefit justifies potential risk to fetus. Monitor for maternal sedation and anticholinergic effects. |
| 3rd trimester | Limited data; risk cannot be excluded. Due to anticholinergic effects, may theoretically cause neonatal adverse effects (e.g., irritability, abnormal muscle tone) if used near term. Use only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for OPTIMINE (OPTIMINE).
| Placental transfer | Based on molecular weight and lipophilicity, cyproheptadine is expected to cross the placenta. However, specific data on placental transfer in humans are lacking. |
| Breastfeeding |
■ FDA Black Box Warning
Chronic immunosuppression increases the risk of malignancy, particularly lymphoma and skin cancer. Therapy should be reserved for patients refractory to conventional treatment.
| Serious Effects |
Hypersensitivity to cyproheptadine or any componentNeonates and premature infantsNarrow-angle glaucomaBladder neck obstructionSymptomatic prostatic hypertrophyStenosing peptic ulcerPyloroduodenal obstructionConcurrent use of MAO inhibitorsLactation (relative contraindication; avoid if possible)
| Precautions | Monitor for bone marrow suppression (leukopenia, thrombocytopenia), hepatotoxicity, and increased risk of infection. TPMT testing recommended before initiation. Avoid live vaccines. |
| Food/Dietary | Avoid alcohol and grapefruit juice. Grapefruit may increase systemic exposure to antihistamines. Food does not significantly alter absorption. |
Loading safety data…
| Cyproheptadine is excreted into breast milk in small amounts. Single doses likely safe, but long-term use or high doses may lead to infant sedation, irritability, or anticholinergic effects (e.g., dry mouth, constipation). Monitor infant for drowsiness and feeding difficulties. Alternative antihistamines (e.g., loratadine) are preferred for chronic use. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy Category B: No evidence of teratogenicity in animal studies. Insufficient human data; risk cannot be excluded in first trimester. Second and third trimester: potential for neonatal respiratory depression, hypotonia, and withdrawal symptoms if used near term. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and respiratory function. Fetal assessment: non-stress test and biophysical profile if maternal hypotension or reduced placental perfusion suspected. |
| Fertility Effects | No known adverse effects on fertility in animal studies. Human data limited; may delay ovulation in women with preexisting menstrual irregularities due to prolactin elevation. |
| Clinical Pearls | OPTIMINE (azatadine) is a first-generation antihistamine with anticholinergic properties. Onset of action is 1-2 hours; duration 12-24 hours. Sedation is prominent; caution when driving. May cause urinary retention, dry mouth, blurred vision. Avoid in narrow-angle glaucoma, prostatic hypertrophy, and MAOI use. |
| Patient Advice | Take exactly as prescribed; do not exceed recommended dose. · May cause drowsiness; avoid driving or operating machinery until you know how you react. · Avoid alcohol and other CNS depressants as they can increase sedation. · Report any vision changes, difficulty urinating, or severe dry mouth. · If pregnant or breastfeeding, discuss risks with your healthcare provider. |